Your healthcare provider may do a blood test of your white blood cells before you start taking ZEPOSIA.Ĭall your healthcare provider right away if you have any of these symptoms of an infection during treatment with ZEPOSIA and for 3 months after your last dose of ZEPOSIA: This will usually go back to normal within 3 months of stopping treatment. ZEPOSIA lowers the number of white blood cells (lymphocytes) in your blood.
ZEPOSIA can increase your risk of serious infections that can be life-threatening and cause death. ZEPOSIA may cause serious side effects, including: Talk to your healthcare provider before taking ZEPOSIA if you have any of these conditions or do not know if you have any of these conditions. take certain medicines called monoamine oxidase (MAO) inhibitors (such as selegiline, phenelzine, linezolid).have untreated, severe breathing problems during your sleep (sleep apnea).have or have had a history of certain types of an irregular or abnormal heartbeat (arrhythmia) that is not corrected by a pacemaker.have had a heart attack, chest pain (unstable angina), stroke or mini-stroke (transient ischemic attack or TIA), or certain types of heart failure in the last 6 months.Bristol-Myers Squibb Company reserves the right to rescind, revoke, or amend this program at any time without notice. Void where prohibited by law, taxed, or restricted.
Once coverage is approved by the patient’s commercial insurance plan, the patient will no longer be eligible. Eligibility will be re-verified in January for patients continuing into the following year, and may be at other times during program participation. Appeal of any prior authorization denial must be made within 90 days or as per payer guidelines, to remain in the program. The Bridge Program is not available to patients who have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs (VA), or Department of Defense (DoD) programs and is available for no more than 12 months to patients in MA, MN, and RI. The Bridge Program is available at no cost for eligible, commercially insured, on-label diagnosed patients if there is a delay in determining whether commercial prescription coverage is available, and is not contingent on any purchase requirement, for up to 24 months (dispensed in 30-day increments).
0 kommentar(er)
